Skip to content

Therapeutic efficacy of percutaneous ultrasound introduction of astragalus medicinal solution in the treatment of postoperative gastrointestinal dysfunction of peritoneal tumors

Therapeutic efficacy of percutaneous ultrasound introduction of astragalus medicinal solution in the treatment of postoperative gastrointestinal dysfunction of peritoneal tumors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000860
Enrollment
Unknown
Registered
2026-04-02
Start date
2025-12-15
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal cancer

Interventions

Experimental Group :Experimental Group (Transdermal Ultrasound Delivery + AstragalusSolution): The Astragalussolution was delivered via transdermal ultrasound to the acupoints Zusanli (ST36), Liangqi
Placebo Control Group :Placebo Control Group (Transdermal Ultrasound Delivery + AstragalusSolution Placebo): The Astragalussolution placebo was delivered via transdermal ultrasound to the acupoints Zu
Blank Control Group:Blank Control Group (Conventional Postoperative Western Medical Therapy): This group received only conventional postoperative Western medical therapy

Sponsors

Beijing Shijitan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Confirmed diagnosis of gastrointestinal dysfunction following peritoneal cancer surgery, based on standardized Western medical diagnostic criteria. 2. Aged between 18 and 75 years, inclusive, with no restrictions based on gender. 3. Karnofsky Performance Status (KPS) score = 60, with a life expectancy greater than 3 months. 4. Absence of severe cardiac, hepatic, or renal diseases, and having provided signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with a history of intestinal obstruction or perforation prior to surgery. 2. Postoperative diagnosis of mechanical intestinal obstruction or intra-abdominal infection. 3. Allergy to any component of Astragalusor contraindications to ultrasound therapy (e.g., skin lesions/breaks, pregnancy, presence of a cardiac pacemaker). 4. Comorbid psychiatric disorders or inability to cooperate with the treatment and follow-up protocol. 5. Lack of essential clinical data precluding objective evaluation of therapeutic efficacy.

Design outcomes

Primary

MeasureTime frame
Time to first flatus? Time to first defecation? ;

Secondary

MeasureTime frame
I-FEED;Gastrointestinal Function Score; TCM Syndrome Score;

Countries

China

Contacts

Public ContactJiang Min

Beijing Shijitan Hospital, Capital Medical University

jiangm1965@sina.com133 1110 8797

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026